Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. MONURIL ADULTE (fosfomycine trométamol)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MONURIL ADULTE (fosfomycine trométamol)

Medicine - Posted on Oct 21 2015 - Updated on Jun 12 2019
Active substance (DCI)
  • fosfomycine trométamol
history (4)
  • 9/23/15

    MONURIL ADULTE (fosfomycine trométamol)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 1/5/11

    MONURIL ADULTES (fosfomycine trométamol)

    MONURIL ADULTES (fosfomycine trométamol)
    icône flèche
  • 10/18/06

    MONURIL (fosfomycine trométamol)

    MONURIL (fosfomycine trométamol)
    icône flèche
  • 1/10/01

    MONURIL ADULTE 3 g, granulé pour solution buvable en sachet (B/1)

    MONURIL ADULTE 3 g, granulé pour solution buvable en sachet (B/1)
    icône flèche
Technical information
ATC code
  • J01XX01
Manufacturer
ZAMBON FRANCE
Presentation

MONURIL 3 g, granulés pour solution buvable en sachet (code CIS : 67951706) 1 sachet(s) aluminium polyéthylène papier de 8 g - Code CIP : 3400933209230

All our publications
    Bacterial infections Drug therapy Urinary bladder diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
ZC0gT8Cet3BuLdNP